Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · Real-Time Price · USD
2.330
-0.040 (-1.69%)
Oct 3, 2025, 3:25 PM EDT - Market open

Company Description

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases.

The company’s lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425.

It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets.

In addition, the company is involved in the advancement of its lead TRIM7 inhibitors through preclinical development as future internal pipeline candidates in oncology.

Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Shattuck Labs, Inc.
Shattuck Labs logo
CountryUnited States
Founded2016
IPO DateOct 9, 2020
IndustryBiotechnology
SectorHealthcare
Employees44
CEOTaylor Schreiber

Contact Details

Address:
500 West 5th Street, Suite 1200
Austin, Texas 78701
United States
Phone512 900 4690
Websiteshattucklabs.com

Stock Details

Ticker SymbolSTTK
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$17.00
CIK Code0001680367
CUSIP Number82024L103
ISIN NumberUS82024L1035
Employer ID81-2575858
SIC Code2834

Key Executives

NamePosition
Dr. Taylor H. Schreiber M.D., Ph.D.Co-Founder, Chief Executive Officer and Director
Andrew R. Neill M.B.A.Chief Financial Officer
Dr. Arunthathy Nirmalini Pandite M.B.A., M.D.Chief Medical Officer
Dr. Abhinav A. Shukla Ph.D.Chief Technical Officer
Dr. Stephen Stout J.D., Ph.D.General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
Casi DeYoungChief Business Officer
Dr. Thomas Lampkin Pharm.D.Senior Vice President of Regulatory Affairs
Suresh de Silva Ph.D.Chief Scientific Officer
Kelli Collin M.S.Senior Vice President of Quality

Latest SEC Filings

DateTypeTitle
Sep 30, 2025424B3Prospectus
Sep 26, 2025EFFECTNotice of Effectiveness
Sep 18, 2025S-3Registration statement under Securities Act of 1933
Sep 2, 2025SCHEDULE 13DFiling
Aug 26, 2025SCHEDULE 13D/AFiling
Aug 26, 20258-KCurrent Report
Aug 14, 202510-QQuarterly Report
Aug 14, 20258-KCurrent Report
Aug 6, 2025SCHEDULE 13D/AFiling
Aug 5, 20258-KCurrent Report